
Toripalimab, camrelizumab, and tislelizumab combined with chemotherapy have shown promising results in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). The results indicated that the immunotherapy combinations significantly improved overall and progression-free survival. However, the additional costs associated with these treatments were substantial. Among the three combinations, toripalimab plus chemotherapy was identified as the most cost-effective option.
Like
Save
Share